Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

PsyBio Therapeutics Corp PSYBF

Healthcare Biotechnology
PsyBio Therapeutics Corp. is a Canada-based biotechnology company. The Company is focused on discovering, designing and developing psycho-focused therapeutics to improve mental and neurological conditions. It is focused on understanding the value of tryptamines and other related psycho-targeted molecules as therapeutic candidates to improve mental and neurological health. The Company is engaged in research and development for occurring psychoactive tryptamines, which is originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines, and combinations thereof. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon, which to develop precursors and analogs, both naturally and non-naturally occurring.


GREY:PSYBF - Post by User

PsyBio Therapeutics Corp > Webinar and New Low For the Year?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(70)
•••
Comment by Bookworm28on May 18, 2021 10:02pm
114 Views
Post# 33227834

RE:RE:RE:RE:RE:RE:Webinar and New Low For the Year?

RE:RE:RE:RE:RE:RE:Webinar and New Low For the Year?I hope you'r right ValueValue123 when you say the OTDQB listing, and DTC eligibility should be the turning point.

I like the science, but that only goes so far when you're a mile underwater and the tide just keeps rising. I think the market maker and the IR guys have to take some responsibility for the low daily volumes and declining price. The company is in good shape, the science and their collaboration with the U of M should translate into something more than what we're seeing. glta
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities